HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
- HeartBeam, Inc. demonstrates significant advancements in atrial flutter detection using HeartBeam AI with VCG.
- Vivek Reddy, MD, presents the data at the EHRA conference, highlighting the superior performance of the AI algorithms.
- The study shows a 28% improvement in sensitivity for VCG compared to single-lead ECGs, maintaining high specificity levels.
- HeartBeam AI proves to be a promising technology for enhancing cardiac care through personalized insights.
- None.
The recent findings presented by HeartBeam, Inc. regarding the efficacy of their AI-driven vectorcardiography (VCG) technology in detecting atrial flutter are noteworthy. Atrial flutter, a heart rhythm disorder, poses diagnostic challenges and can lead to serious complications if not identified and managed appropriately. The current standard for diagnosis is the 12-lead ECG, which is not as readily available as single-lead ECG systems found in consumer wearables.
The reported 28% improvement in detection rates over single-lead ECGs is a significant leap forward. This enhancement could potentially lead to better patient outcomes through earlier detection and treatment. Moreover, the high specificity rate of 98.7% implies that false positives are minimal, which is important in preventing unnecessary treatments that can arise from misdiagnosis.
From a medical perspective, integrating such AI technology into routine clinical practice could revolutionize the way cardiac arrhythmias are monitored, especially in outpatient settings or remote areas where access to comprehensive ECG equipment may be limited.
HeartBeam's AI technology's potential market impact is substantial, given the increasing prevalence of wearable technology in healthcare. The global market for smartwatches and fitness trackers is expanding, with consumers becoming more health-conscious and seeking devices that offer advanced health monitoring features.
HeartBeam's advancement positions them favorably within the digital health sector, especially in the cardiology sub-segment. The ability of their AI algorithm to operate with a high degree of accuracy in concert with VCG could see them capture a significant share of the market, especially if their technology is integrated into consumer wearables. This could disrupt the current landscape where 12-lead ECGs are the gold standard, offering a more accessible and cost-effective solution for cardiac monitoring.
Investors might view this as an opportunity for growth, especially if HeartBeam secures partnerships with wearable manufacturers or gains traction in telehealth services. However, the adoption rate will depend on regulatory approvals, clinical adoption and the scalability of their technology.
The announcement by HeartBeam, Inc. is likely to have a positive influence on investor sentiment, as it presents a technological advancement with the potential to capture a new market segment. The financial implications hinge on the company's ability to commercialize their AI and VCG technology effectively.
Investors will be looking at the company's roadmap for regulatory approval, as well as their strategy for market penetration and partnership formation. The costs associated with these processes, along with the timeline for revenue generation, will be critical factors in assessing the company's financial health and stock valuation.
Given the specificity and sensitivity rates reported, the technology could become a new standard for atrial flutter detection, which may lead to a reevaluation of the company's long-term revenue potential. However, it is essential to consider the costs of R&D, marketing and sales as they scale up operations. A careful analysis of their balance sheet and cash flow statements in subsequent quarters will provide a clearer picture of the financial impact of this technological development.
New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology
Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables
In the study, HeartBeam AI with VCG demonstrated a
Smartwatches have become increasingly popular for detecting and monitoring abnormalities in the timing or pattern of heartbeats but only offer a single-lead ECG, which greatly limits their ability to detect a broad range of cardiac irregularities. Atrial flutter is a common irregularity, or arrhythmia, that typically requires a healthcare professional to administer a 12-lead ECG in a medical setting which is not always practical or even possible at the time of a cardiac event.
HeartBeam’s core vectorelectrocardiography (3D VECG) technology captures the heart’s signals in three projections (X, Y, Z), similar to VCG, and synthesizes a 12-lead ECG. The technology is designed to be used in HeartBeam’s small, portable, patient-friendly devices that allow for remote cardiac monitoring. The Company’s first planned application of the 3D VECG platform technology is the HeartBeam AIMIGo™, a credit card-sized device for patient use at home or anywhere, which is currently under review with FDA.
“The study presented at the EHRA conference shows that HeartBeam AI combined with VCG delivers equivalent performance to a 12-lead ECG and greatly improves detection of atrial flutter over a single-lead ECG, underscoring the limitations of current wearable technologies. This presents an opportunity for a VCG-based algorithm that offers arrhythmia detection capabilities beyond what is available today and to fill gaps in healthcare inequality when obtaining a 12-lead ECG is challenging,” said Dr. Reddy.
The HeartBeam technology gathers far more data than a single-lead ECG. By leveraging AI to analyze these data-rich signals, HeartBeam believes it will be able to improve diagnostic accuracy and the technology has the potential to extract unique information that could go beyond today’s 12-lead ECGs as data of great diagnostic value is gathered from the same patients using the device over time. HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.
“The intent of our AI program is to leverage our novel VECG platform to unlock detection and prediction capabilities currently limited to healthcare facilities and make them readily accessible and available to the patient, and this new data is a clear example of what we can accomplish,” said Branislav Vajdic, PhD, CEO and Founder of HeartBeam. “As we continue to expand our artificial intelligence capabilities, we look forward to demonstrating how the combination of our data rich 3D VECG platform with HeartBeam AI has the potential to transform how cardiac health is managed in the future.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that is dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (VECG) technology collects 3D signals of the heart’s electrical activity and converts them into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining how cardiac health is managed in the future. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409880945/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
FAQ
What technology did HeartBeam, Inc. present data on at the EHRA conference?
What is the ticker symbol for HeartBeam, Inc.?
Who presented the data at the EHRA conference?
What was the improvement percentage in atrial flutter detection using VCG over single-lead ECGs?
What was the specificity percentage for VCG in the study?
